With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

Disease-modifying therapies (DMT) for Alzheimer's disease (AD) are highly longed-for. In
this quest, anti-amyloid therapies take center stage supported by genetic facts that highlight …

Abstract Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most
accurate diagnostic markers for Alzheimer's disease. No studies have compared the clinical …

Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s
disease pathology - PMC Back to Top Skip to main content NIH NLM Logo Access keys …

INTRODUCTION Detection of Alzheimer's disease (AD) pathophysiology among individuals
with mild cognitive changes and those experiencing subjective cognitive decline (SCD) …

Background Converging evidence suggests that markers of Alzheimer's disease (AD)
pathology in cognitively unimpaired older individuals are associated with high risk of …

Background and objectives This study evaluates the discriminative performance of the
automated Lumipulse plasma pTau-217 compared to plasma pTau-181 and the Aβ42/Aβ40 …

Background Maximizing the efficiency to screen amyloid-positive individuals in
asymptomatic and non-demented aged population using blood-based biomarkers is …